According to Sarepta Therapeutics 's latest financial reports the company's total liabilities are $2.40 B. A companyโs total liabilities is the sum of all current and non-current debts and obligations.
Year | Total liabilities | Change |
---|---|---|
2023-12-31 | $2.40 B | -12.33% |
2022-12-31 | $2.74 B | 23.58% |
2021-12-31 | $2.21 B | -0.13% |
2020-12-31 | $2.22 B | 121.27% |
2019-12-31 | $1.00 B | 64.75% |
2018-12-31 | $0.60 B | 17.55% |
2017-12-31 | $0.51 B | 493.44% |
2016-12-31 | $87.41 M | 4.77% |
2015-12-31 | $83.43 M | 76.1% |
2014-12-31 | $47.38 M | 6.77% |
2013-12-31 | $44.37 M | -45.43% |
2012-12-31 | $81.31 M | 248.22% |
2011-12-31 | $23.35 M | -52.14% |
2010-12-31 | $48.79 M | 34.06% |
2009-12-31 | $36.39 M | 271.25% |
2008-12-31 | $9.8 M | -20.01% |
2007-12-31 | $12.25 M | 288.98% |
2006-12-31 | $3.15 M | 14.66% |
2005-12-31 | $2.74 M | 22.15% |
2004-12-31 | $2.24 M | -40.03% |
2003-12-31 | $3.75 M | -26.77% |
2002-12-31 | $5.12 M | 56.11% |
2001-12-31 | $3.28 M |
Company | Total liabilities | differencediff. | Country |
---|---|---|---|
Gilead Sciences GILD | $39.37 B | 1,537.09% | ๐บ๐ธ USA |
PTC Therapeutics
PTCT | $2.71 B | 12.85% | ๐บ๐ธ USA |
Novavax NVAX | $2.51 B | 4.54% | ๐บ๐ธ USA |
Alnylam Pharmaceuticals
ALNY | $4.05 B | 68.40% | ๐บ๐ธ USA |
Insmed INSM | $1.66 B | -30.91% | ๐บ๐ธ USA |
BioCryst Pharmaceuticals
BCRX | $0.97 B | -59.57% | ๐บ๐ธ USA |
Avidity Biosciences RNA | $0.12 B | -94.69% | ๐บ๐ธ USA |